Literature DB >> 23874508

Best practices and joint calling of the HumanExome BeadChip: the CHARGE Consortium.

Megan L Grove1, Bing Yu, Barbara J Cochran, Talin Haritunians, Joshua C Bis, Kent D Taylor, Mark Hansen, Ingrid B Borecki, L Adrienne Cupples, Myriam Fornage, Vilmundur Gudnason, Tamara B Harris, Sekar Kathiresan, Robert Kraaij, Lenore J Launer, Daniel Levy, Yongmei Liu, Thomas Mosley, Gina M Peloso, Bruce M Psaty, Stephen S Rich, Fernando Rivadeneira, David S Siscovick, Albert V Smith, Andre Uitterlinden, Cornelia M van Duijn, James G Wilson, Christopher J O'Donnell, Jerome I Rotter, Eric Boerwinkle.   

Abstract

Genotyping arrays are a cost effective approach when typing previously-identified genetic polymorphisms in large numbers of samples. One limitation of genotyping arrays with rare variants (e.g., minor allele frequency [MAF] <0.01) is the difficulty that automated clustering algorithms have to accurately detect and assign genotype calls. Combining intensity data from large numbers of samples may increase the ability to accurately call the genotypes of rare variants. Approximately 62,000 ethnically diverse samples from eleven Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium cohorts were genotyped with the Illumina HumanExome BeadChip across seven genotyping centers. The raw data files for the samples were assembled into a single project for joint calling. To assess the quality of the joint calling, concordance of genotypes in a subset of individuals having both exome chip and exome sequence data was analyzed. After exclusion of low performing SNPs on the exome chip and non-overlap of SNPs derived from sequence data, genotypes of 185,119 variants (11,356 were monomorphic) were compared in 530 individuals that had whole exome sequence data. A total of 98,113,070 pairs of genotypes were tested and 99.77% were concordant, 0.14% had missing data, and 0.09% were discordant. We report that joint calling allows the ability to accurately genotype rare variation using array technology when large sample sizes are available and best practices are followed. The cluster file from this experiment is available at www.chargeconsortium.com/main/exomechip.

Entities:  

Mesh:

Year:  2013        PMID: 23874508      PMCID: PMC3709915          DOI: 10.1371/journal.pone.0068095

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


Introduction

Exome- and whole-genome sequencing is becoming increasingly affordable and allows for detection and genotyping of rare variants in the human genome. Yet, genotyping arrays remain a cost-effective approach when investigating genetic polymorphisms previously identified in large populations. A limitation of using arrays to genotype rare variants is the difficulty that automated clustering algorithms have to accurately detect and assign accurate genotype calls [1], [2]. Large sample sizes increase the number of occurrences of rare variants and, therefore, should facilitate automated clustering and genotyping. An array focused on rare and low frequency coding variation, hereafter referred to as the exome chip, has been developed by querying the exomes sequenced in ∼12,000 individuals and aggregating the variation that is seen in more than two individuals in more than two sequencing efforts (http://genome.sph.umich.edu/wiki/Exome_Chip_Design). Participating studies in the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium [3] consented to have their Illumina Infinium HumanExome BeadChip intensity data analyzed collectively (n = 62,266) in order to increase the accuracy of rare variant genotype calls. The resulting cluster file (.egt) is publically available and we show that its use, along with best practices, increase genotype accuracy compared to other methods alone.

Results

Genotypes were obtained for 238,876 successful variants in accordance with our best practices (96.4% SNP pass rate) which were converted to PLINK format [4] by cohort and combined into a single aggregate file for further analyses. Of the 62,266 samples genotyped, 1,380 (2.2%) had a GenCall quality score in the lower 10th percentile of the distribution across all variants genotyped (p10GC) <0.38 or call rate <0.97 and were excluded from allele frequency calculations. Because founder effects and unique population structure have been previously observed in Icelandic samples [5], [6], the Age, Gene/Environment, Susceptibility-Reykjavik study was excluded from subsequent steps. Known duplicated samples, individuals without self-reported race, and the HapMap controls were also removed. After excluding duplicate variants (n = 811), the minor allele frequencies (MAF) for 238,065 successful SNPs and 56,407 samples by self-reported race are described in Table 1. There were 10,693 monomorphic SNPs (4.5%), and 78.6% of the variants on the exome chip have a MAF <0.005. Allele frequencies for each variant by race group are reported in the SNP information file (see Methods and Data Access sections). Ethnicity specific HapMap allele frequencies for the 96 controls (48 CEU and 48 YRI) and genotypes are also available.
Table 1

Exome chip minor allele frequency distribution by race.

MAF IntervalAfrican AmericansCaucasiansHispanicsAsiansAll
(n = 13,375) (%)(n = 40,102) (%)(n = 2,128) (%)(n = 776) (%)(n = 56,407) (%)
023.616.543.677.54.5
(0, 0.001]36.858.122.33.958.8
(0.001, 0.005]14.68.613.93.915.3
(0.005, 0.01]4.42.33.71.64.3
(0.01, 0.05]7.93.85.13.05.7
(0.05, 0.1]2.71.71.71.41.8
(0.1, 0.2]3.02.42.42.12.4
(0.2, 0.5]7.16.77.36.67.3

The following samples were excluded: all AGES individuals, race unknown or not reported, known replicates, HapMap controls, individuals with p10GC <0.38, and individuals with call rate <0.97. Individuals with race designated as other were included in the overall MAF calculation, but data is not shown separately (n = 26). A total of 238,065 variants were used for calculating minor allele frequencies after excluding those that failed laboratory quality control (n = 8,994) and duplicates (n = 811).

The following samples were excluded: all AGES individuals, race unknown or not reported, known replicates, HapMap controls, individuals with p10GC <0.38, and individuals with call rate <0.97. Individuals with race designated as other were included in the overall MAF calculation, but data is not shown separately (n = 26). A total of 238,065 variants were used for calculating minor allele frequencies after excluding those that failed laboratory quality control (n = 8,994) and duplicates (n = 811). To evaluate the performance of the rare variant calling approach (see Methods), we compared exome chip genotypes derived from three calling methods to available exome sequencing data in 530 ARIC individuals. First, exome chip genotypes were called with the Illumina issued cluster file HumanExome-12v1.egt (see Data Access section for file location) (Dataset I). Second, we used zCall (threshold set to 7) [7] to determine genotypes for the missing variant calls in Dataset I to create Dataset Z. Third, we used the CHARGE best practices (see Data Access) and joint calling approach described to ascertain exome chip genotypes (Dataset C). A total of 185,119 variants that were present in the exome sequence dataset and passed our best practices were compared using genotype concordance and uncertainty coefficient tests. Results are presented in Table 2. The uncertainty coefficients indicate that we can predict 86.4% of the information (entropy) in the exome sequence data when using the Illumina cluster file, 91.2% when using the zCall algorithm, and 93.4% when the CHARGE clustering method was utilized.
Table 2

Results of missing data, genotype discordance, uncertainty coefficients and frequencies of exome chip data ascertained by three calling methods and compared to exome sequence genotypes.

Exome SequenceExome ChipMissingDiscordanceUncertainty
GenotypesGenotypes(%)(%)Coefficient
Dataset I AA AB BB XX Total
AA 94,878,50133,6794,467183,95295,100,599
AB 41,3952,350,6444,77715,9672,412,783
BB 3,6584,642495,6261,809505,735
XX 89,1042,9057111,23393,953
Total 95,012,6582,391,870505,581202,96198,113,0700.300.090.864
Dataset Z AA AB BB XX Total
AA 94,964,611115,8494,39415,74595,100,599
AB 41,8642,365,4625,1373202,412,783
BB 3,5575,635496,351192505,735
XX 89,4802,99671476393,953
Total 95,099,5122,489,942506,59617,02098,113,0700.110.180.912
Dataset C AA AB BB XX Total
AA 95,023,65333,4424,43039,07495,100,599
AB 41,8502,363,6643,9693,3002,412,783
BB 3,6064,646496,897586505,735
XX 89,3912,93070692693,953
Total 95,158,5002,404,682506,00243,88698,113,0700.140.090.934

A total of 185,119 variants were used for these analyses, excluding duplicated variants, short insertion/deletions, XY chromosome SNPs, Y chromosome SNPs, mitochondrial SNPs, sites not identified in the exome sequencing dataset, and failing SNPs as identified by the CHARGE best practices guidelines. Genotype classes are represented as AA = common variant homozygote, AB = heterozygote, BB = rare variant homozygote, and XX = missing data. Dataset I: exome chip genotypes called with Illumina cluster file. Dataset Z: zCall assigned genotypes to missing data in Dataset I. Dataset C: exome chip genotypes called with the CHARGE cluster file.

A total of 185,119 variants were used for these analyses, excluding duplicated variants, short insertion/deletions, XY chromosome SNPs, Y chromosome SNPs, mitochondrial SNPs, sites not identified in the exome sequencing dataset, and failing SNPs as identified by the CHARGE best practices guidelines. Genotype classes are represented as AA = common variant homozygote, AB = heterozygote, BB = rare variant homozygote, and XX = missing data. Dataset I: exome chip genotypes called with Illumina cluster file. Dataset Z: zCall assigned genotypes to missing data in Dataset I. Dataset C: exome chip genotypes called with the CHARGE cluster file. These data demonstrate the importance of implementing stringent laboratory quality control measures in addition to the clustering algorithms and rare variant calling approaches tested. The complete list of 8,994 failing SNPs identified in the jointly called exome chip project are available for download on the CHARGE public website. Genotypes ascertained with the CHARGE jointly called exome chip cluster file (Dataset C) were 99.77% concordant with sequence data, 0.14% were missing in exome chip data, in the exome sequence data, or both, and 0.09% were discordant (Figure 1). Heterozygotes in Dataset C were most often misclassified when compared to the common allele homozygote, and mismatches were attributed equally to both sequencing and genotyping (Table 2).
Figure 1

Results of CHARGE exome chip genotype calls compared to exome sequence data in 530 individuals.

We also tested the ability of the CHARGE exome chip cluster file to accurately assign genotypes in the three rarest variant bins: singletons (minor allele count = 1), doubletons (minor allele count = 2), and tripletons (minor allele count = 3). We observed high concordance between exome chip singletons (99.99%), doubletons (99.98%), and tripletons (99.97%) when compared to their respective sequence genotypes in the same 530 ARIC individuals previously described (data not shown). These results are consistent with the global concordance tests which suggest we are able to accurately call very rare variants.

Discussion

The results presented here demonstrate that rare variants on the exome chip can be accurately called when using a large, combined cluster file and best practices described when compared to existing clustering algorithms and rare variant calling methods. The joint calling protocol, accompanying cluster file, list of poor performing variants on the chip, and annotation data are a valuable resource for the scientific community and will be of great utility to those having smaller sample sets where the calling of rare variants is problematic. All new projects will require user decisions based on their own cohort data and the metrics and best practices presented here should be updated accordingly.

Materials and Methods

Subjects

Data from 62,266 participants from the following eleven studies in the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium [3] were included in this joint calling experiment and study descriptions were published previously: Age, Gene/Environment, Susceptibility-Reykjavik (AGES) Study [8], Atherosclerosis Risk in Communities (ARIC) Study [9], Cardiac Arrest Blood Study (CABS) [10], Cardiovascular Health Study (CHS) [11], [12], Coronary Artery Risk Development in Young Adults (CARDIA) [13], [14], Multi-Ethnic Study of Atherosclerosis (MESA) [15], Family Heart Study (FamHS) [16], Framingham Heart Study (FHS) [17], Health, Aging, and Body Composition (HABC) Study [18], Jackson Heart Study (JHS) [19], and the Rotterdam Study (RS) [20]–[23]. In addition, we genotyped 96 unrelated HapMap samples (48 CEU and 48 YRI) with each cohort and the list of sample IDs are available as a reference on the CHARGE exome chip public website.

Ethics Statement

All subjects provided written and informed consent to participate in genetic studies, and all study sites received approval to conduct this research from their local respective Institutional Review Boards (IRB) as follows: „The National Bioethics Committee“ and „The Data Protection Authority“ (AGES); University of Mississippi Medical Center IRB (ARIC – Jackson Field Center), Wake Forest University Health Sciences IRB (ARIC – Forsyth County Field Center), University of Minnesota IRB (ARIC – Minnesota Field Center), and Johns Hopkins University (Bloomberg School of Public Health) IRB (ARIC – Washington County Field Center); University of Washington IRB (CABS); Wake Forest University Health Sciences IRB (CHS – Forsyth County Field Center), University of California, Davis IRB (CHS – Sacramento County Field Center), Johns Hopkins University (Bloomberg School of Public Health) IRB (CHS – Washington County Field Center), and University of Pittsburgh IRB (CHS – Pittsburgh Field Center); University of Alabama at Birmingham (CARDIA – Birmingham Field Center), Northwestern University IRB (CARDIA – Chicago Field Center), University of Minnesota IRB (CARDIA – Minneapolis Field Center), and Kaiser Permanente IRB (CARDIA – Oakland Field Center); Washington University IRB (FamHS); Boston University IRB (FHS); Wake Forest University Health Sciences IRB (HABC); University of Mississippi Medical Center IRB (JHS); Columbia University IRB (MESA – New York Field Center), Johns Hopkins University IRB (MESA – Baltimore Field Center), Northwestern University IRB (MESA – Chicago Field Center), University of California IRB (MESA – Los Angeles Field Center), University of Minnesota IRB (MESA – Twin Cities Field Center), Wake Forest University Health Sciences IRB (MESA – Winston-Salem Field Center) and the National Heart, Lung, and Blood Institute; Medisch Ethische Toetsings Commissie (METC) at the Erasmus Medical Center, and the Netherlands Ministry of Health, Welfare and Sport (VWS) (RS). Joint calling of the array data was approved by the Committee for the Protection of Human Subjects (CPHS) which serves as the IRB for the University of Texas Health Science Center at Houston.

Genotyping

Study samples were processed on the HumanExome BeadChip v1.0 (Illumina, Inc., San Diego, CA) querying 247,870 variable sites described elsewhere (see Data Access) using standard protocols suggested by the manufacturer at the following seven genotyping centers: Broad Institute (JHS), Cedars-Sinai Medical Center (CHS, FamHS and MESA), Erasmus Medical Center (RS), Illumina Fast Track Services (FHS), University of Texas Health Science Center at Houston (AGES, ARIC and CARDIA), University of Washington (CABS), and Wake Forest University (HABC). Each center genotyped a common set of 96 HapMap samples to be utilized for quality control and determination of batch effects. The two channel raw data files (.idat) for all samples were transferred to a central location and assembled into a single project for joint calling. A summary of the samples genotyped within each cohort by race and gender is described in Table 3. The following variables were provided for each sample included in the project: study specific sample ID, cohort name, sample type (DNA or WGA), race (self-reported), gender, sample plate, sample well, chip barcode, chip position, replicate ID, father and mother IDs (if applicable).
Table 3

Sample sizes of cohorts participating in joint calling effort by gender and self-reported race.

CohortAfrican AmericansCaucasiansHispanicsAsiansOtherHapMapsReplicatesTotal
MFMFMFMFMFMFMFU1
AGES001,3051,76700000024246903,135
ARIC1,1211,8325,1985,8730000007776629020014,529
CABS2831723,7011,1740000005759932905,568
CHS3185262,0082,603001314134846253405,639
CARDIA9001,1851,0631,1890000004848183004,481
FamHS2134099331,19100000014231002,784
FHS003,7024,4750000007569477608,444
HABC51568093083900000048477503,071
JHS1,0631,7950000000064640002,986
MESA1,1291,4641,2821,3979781,151387386004444513908,352
RS001,4591,72000000047470043,277
Total 5,542 8,063 21,581 22,288 978 1,151 388 389 14 13 546 547 310 312 204 62,266

Gender is unavailable for blinded replicates in the ARIC study and four RS samples.

Gender is unavailable for blinded replicates in the ARIC study and four RS samples.

Clustering, Genotype Calling and Laboratory Quality Control

The Illumina GenomeStudio v2011.1 software was utilized with the GenTrain 2.0 clustering algorithm. Genomic DNA study samples and HapMap controls with call rates >99% (n = 55,142) were used to define genotype clusters with races combined and reruns excluded. The no-call threshold was set to 0.15 and we excluded female Y SNPs when calculating SNP statistics. The genotype quality score, representing the 10th percentile of the distribution of GenCall scores across all SNPs genotyped (p10GC), was visually examined in a scatter plot across all samples (Index vs. p10GC). Samples with an empirically determined p10GC <0.38 were identified as outliers and flagged for exclusion. The SNP parameters “Expected Number of Clusters of Y SNPs” and “Expected Number of Clusters of mtSNPs” were set to 2. Following automated clustering, all variants meeting the criteria provided in Table 4 (n = 107,175) were visually inspected and manually clustered, if possible, by two independent laboratory technicians. AA and BB theta deviation cutoffs were determined empirically. Variants removed from the HumanExome BeadChip v1.1 (n = 4,969) and cautious sites, as defined by the exome chip design committee (n = 333) (ftp://share.sph.umich.edu/exomeChip/IlluminaDesigns/cautiousSites/cautiousSite.sorted.sites), were also inspected. Samples with a call rate between 0.95 and 0.99 that had been previously excluded were brought back in to the project and re-inspected based on the criteria listed in Table 4. This additional review was necessary as the CHARGE exome chip project contains samples from multiple DNA sources and ethnicities that were genotyped at several centers. SNPs exhibiting obvious batch effects were excluded. After joint calling, reproducibility and heritability statistics, SNP statistics and sample statistics were updated and the SNP-level quality control criteria described in Table 5 were implemented. SNPs with reproducibility (rep) errors >2, parent-parent-child (PPC) error >1, or parent-child (PC) error >1 were not excluded, but were flagged and reported back to the participating studies for further investigation. A list of the 8,994 excluded variants is provided on the CHARGE exome chip website as cluster positions for these sites are zeroed out in the.egt file (note: all SNP statistics for these sites will be converted to zero when the cluster file is imported into the Genome Studio project). A portion of excluded SNPs may be recoverable in projects with a homogenous population substructure, and we recommend clustering and reviewing the subset of variants with the user’s high quality samples. Table 6 describes the exome chip content and number of variants excluded by functional category (see Annotation). Importantly, the v1.0 cluster file should not be used for calling the Illumina v1.1 exome chip as the two versions were manufactured with different bead pools.
Table 4

Best practices criteria used to identify SNPs for visual inspection and manual reclustering.

Best Practices Criteria
All X, Y, XY and MT variants
Call frequency between 0.95 and 0.99
Cluster separation <0.4
AB frequency >0.6
AB R mean <0.2
Het excess >0.1
Het excess<−0.9
AA theta mean between 0.2 and 0.3
BB theta mean between 0.7 and 0.8
AB theta mean between 0.2 and 0.3
AB theta mean between 0.7 and 0.8
AA theta deviation >0.025
AB theta deviation ≥0.07
BB theta deviation >0.025
AB frequency = 0 and minor allele frequency >0
AA frequency = 1 and call rate <1
BB frequency = 1 and call rate <1
MAF <0.0001 and call rate ≠ 1
Rep error >2
PPC error >1
PC error >1
Variants removed from v1.1 exome chip
Cautious sites

AA: allele A homozygote; AB: heterozygote; BB: allele B homozygote; Het: heterozygote; MAF: minor allele frequency; MT: mitochondrial; PC: parent-child; PPC: parent-parent-child; R: normalized intensity; Rep, reproducibility.

Table 5

Exome chip SNP exclusion criteria.

Exclusion Criteria
Call frequency <0.95 (except Y chr)
Cluster separation <0.4
AB frequency >0.6
AB R mean <0.2
Het excess >0.1
Het excess<−0.9
AA theta mean >0.3
BB theta mean <0.7
AB theta mean <0.2 or >0.8
AA theta deviation >0.06
AB theta deviation ≥0.07
BB theta deviation >0.06
Obvious batch effects

AA: allele A homozygote; AB: heterozygote; BB: allele B homozygote; Het: heterozygote; R: normalized intensity.

Table 6

Exome chip content and CHARGE excluded variants by functional category.

Category1 Total VariantsVariants Excluded
exonic;stopgain5,193145
exonic;splicing;stopgain901
exonic;stoploss2392
exonic;splicing;stoploss50
splicing2,26360
exonic;splicing;synonymous3,36374
exonic;splicing701
exonic;splicing;nonsynonymous5,237105
exonic;nonsynonymous208,7797,369
exonic;synonymous6,415281
UTR351846
UTR5776
ncRNA_splicing11
ncRNA_exonic1118
ncRNA_UTR380
ncRNA_UTR510
intronic5,762254
ncRNA_intronic44723
downstream18719
upstream1817
upstream;downstream80
intergenic8,549528
indel13710
mitochrondrial22654
no annotation30
Total247,8708,994

dbNSFP was used for annotating variants [27] (see Methods).

AA: allele A homozygote; AB: heterozygote; BB: allele B homozygote; Het: heterozygote; MAF: minor allele frequency; MT: mitochondrial; PC: parent-child; PPC: parent-parent-child; R: normalized intensity; Rep, reproducibility. AA: allele A homozygote; AB: heterozygote; BB: allele B homozygote; Het: heterozygote; R: normalized intensity. dbNSFP was used for annotating variants [27] (see Methods).

Exome Chip Performance

Genotypes derived from available exome sequencing of 540 ARIC participants were used as the comparison dataset to test the performance of the exome chip. We excluded 10 individuals from the sequencing dataset due to a high missing data rate <0.90, or non-overlap of individuals with existing exome chip data. Exome sequencing data is accessible via dbGaP as part of the National Heart Lung and Blood Institute (NHLBI) GO-ESP: Heart Cohorts Component of the Exome Sequencing Project (ARIC) (Study Accession: phs000398.v1.p1). The following variants were excluded from the exome chip dataset as they were not available in the genotype data derived from exome sequencing results: replicate sites that were determined as triallelic or duplicates on opposite strands, short insertion/deletions, XY chromosome SNPs, Y chromosome SNPs, mitochondrial SNPs, or sites not identified in the exome sequencing dataset (n = 56,042). Poor performing variants identified by our best practices criteria were removed if not previously excluded (n = 6,709), thus a total of 185,119 variants were available for concordance analyses in 530 individuals. Since concordance results are potentially high due to rare variation on the exome chip, we also calculated uncertainty coefficients [24] to determine the degree of association between each of the exome chip calling methods and exome sequence data. The uncertainty coefficient is a measure of association that is based on information entropy [25], or the uncertainty in a random variable, that is, a variable subject to chance variations. Uncertainty coefficients are useful when evaluating results obtained from clustering algorithms since genotype classification is usually random (all minor alleles are not classified as either AA or BB), thus the algorithm is not susceptible to rare variation bias in which the more common genotype could have been called by chance alone. See Press et al. (1992), pp. 758–762, for further clarification of the uncertainty coefficient metric [26].

Annotation

Annotation of the v1.0 exome chip variants was performed with dbNSFP [27]. The dbNSFP v2.0 annotations are available on the CHARGE exome chip public website in the SNP information file. dbSNP rs information has been curated and a look up table with the associated Illumina SNP name is also available. The reason for inclusion of the variant on the exome chip by the design team is also provided in the SNP info file (ftp://share.sph.umich.edu/exomeChip/IlluminaDesigns/annotatedList.txt).

Data Access

The following CHARGE supporting documents are located at chargeconsortium.com/main/exomechip: CHARGE_ExomeChip_Best_Practices.pdf, CHARGE_ExomeChip_v1.0_Cluster_File.egt (cluster file for v1.0 chip), CHARGE_ExomeChip_v1.0_Excluded_Variants.txt (list of 8,994 zeroed out variants in cluster file), CHARGE_ExomeChip_SNP_Info_File.tsv.txt and Read Me file includes Illumina annotation, dbNSFP annotation, dbSNP rs numbers, overlapping sites between the HumanExome BeadChip v1.0 and v1.1, reason for inclusion, and race specific allele frequencies for each variant, including HapMap controls. Sample identifiers (CHARGE_ExomeChip_HapMap96_Control_List.csv) and genotypes for the 96 unrelated HapMap controls (CHARGE_ExomeChip_HapMap96_Genotype_Data.csv) are also available. The Illumina genotyping protocol (Infinium_Best_Practices_370-2009-010.pdf) and cluster file (HumanExome-12v1.egt) are available with a MyIllumina login at https://icom.illumina.com/. The exome chip content data sheet is publicly available at http://www.illumina.com/documents/products/datasheets/datasheet_humanexome_beadchips.pdf. zCall is a rare variant caller for array-based genotyping provided by Goldstein et al. and available for download at github.com/jigold/zCall [7]. PLINK is a freely available analysis toolset at http://pngu.mgh.harvard.edu/purcell/plink/ [4].
  24 in total

1.  Cardiovascular risk factors in young adults. The CARDIA baseline monograph.

Authors:  G R Cutter; G L Burke; A R Dyer; G D Friedman; J E Hilner; G H Hughes; S B Hulley; D R Jacobs; K Liu; T A Manolio
Journal:  Control Clin Trials       Date:  1991-02

2.  NHLBI Family Heart Study: objectives and design.

Authors:  M Higgins; M Province; G Heiss; J Eckfeldt; R C Ellison; A R Folsom; D C Rao; J M Sprafka; R Williams
Journal:  Am J Epidemiol       Date:  1996-06-15       Impact factor: 4.897

3.  The Cardiovascular Health Study: design and rationale.

Authors:  L P Fried; N O Borhani; P Enright; C D Furberg; J M Gardin; R A Kronmal; L H Kuller; T A Manolio; M B Mittelmark; A Newman
Journal:  Ann Epidemiol       Date:  1991-02       Impact factor: 3.797

4.  A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes.

Authors:  S Thorlacius; G Olafsdottir; L Tryggvadottir; S Neuhausen; J G Jonasson; S V Tavtigian; H Tulinius; H M Ogmundsdottir; J E Eyfjörd
Journal:  Nat Genet       Date:  1996-05       Impact factor: 38.330

5.  Recruitment of adults 65 years and older as participants in the Cardiovascular Health Study.

Authors:  G S Tell; L P Fried; B Hermanson; T A Manolio; A B Newman; N O Borhani
Journal:  Ann Epidemiol       Date:  1993-07       Impact factor: 3.797

6.  The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC investigators.

Authors: 
Journal:  Am J Epidemiol       Date:  1989-04       Impact factor: 4.897

7.  Multi-Ethnic Study of Atherosclerosis: objectives and design.

Authors:  Diane E Bild; David A Bluemke; Gregory L Burke; Robert Detrano; Ana V Diez Roux; Aaron R Folsom; Philip Greenland; David R Jacob; Richard Kronmal; Kiang Liu; Jennifer Clark Nelson; Daniel O'Leary; Mohammed F Saad; Steven Shea; Moyses Szklo; Russell P Tracy
Journal:  Am J Epidemiol       Date:  2002-11-01       Impact factor: 4.897

8.  CARDIA: study design, recruitment, and some characteristics of the examined subjects.

Authors:  G D Friedman; G R Cutter; R P Donahue; G H Hughes; S B Hulley; D R Jacobs; K Liu; P J Savage
Journal:  J Clin Epidemiol       Date:  1988       Impact factor: 6.437

9.  Dietary intake and cell membrane levels of long-chain n-3 polyunsaturated fatty acids and the risk of primary cardiac arrest.

Authors:  D S Siscovick; T E Raghunathan; I King; S Weinmann; K G Wicklund; J Albright; V Bovbjerg; P Arbogast; H Smith; L H Kushi
Journal:  JAMA       Date:  1995-11-01       Impact factor: 56.272

10.  Determinants of disease and disability in the elderly: the Rotterdam Elderly Study.

Authors:  A Hofman; D E Grobbee; P T de Jong; F A van den Ouweland
Journal:  Eur J Epidemiol       Date:  1991-07       Impact factor: 8.082

View more
  171 in total

1.  Whole-exome Sequence Analysis Implicates Rare Il17REL Variants in Familial and Sporadic Inflammatory Bowel Disease.

Authors:  Mark M Sasaki; Andrew D Skol; Eric A Hungate; Riyue Bao; Lei Huang; Stacy A Kahn; James M Allan; Steven R Brant; Dermot P B McGovern; Inga Peter; Mark S Silverberg; Judy H Cho; Barbara S Kirschner; Kenan Onel
Journal:  Inflamm Bowel Dis       Date:  2016-01       Impact factor: 5.325

2.  Fruit and vegetable intake and vitamin C transporter gene (SLC23A2) polymorphisms in chronic lymphocytic leukaemia.

Authors:  Delphine Casabonne; Esther Gracia; Ana Espinosa; Mariona Bustamante; Yolanda Benavente; Claudia Robles; Laura Costas; Esther Alonso; Eva Gonzalez-Barca; Adonina Tardón; Trinidad Dierssen-Sotos; Eva Gimeno Vázquez; Marta Aymerich; Elies Campo; José J Jiménez-Moleón; Rafael Marcos-Gragera; Gemma Castaño-Vinyals; Nuria Aragones; Marina Pollan; Manolis Kogevinas; Carmen Urtiaga; Pilar Amiano; Victor Moreno; Silvia de Sanjose
Journal:  Eur J Nutr       Date:  2016-02-02       Impact factor: 5.614

3.  Identification of Genetic Variants Linking Protein C and Lipoprotein Metabolism: The ARIC Study (Atherosclerosis Risk in Communities).

Authors:  James S Pankow; Weihong Tang; Nathan Pankratz; Weihua Guan; Lu-Chen Weng; Mary Cushman; Eric Boerwinkle; Aaron R Folsom
Journal:  Arterioscler Thromb Vasc Biol       Date:  2017-01-12       Impact factor: 8.311

4.  Exome-sequencing in a large population-based study reveals a rare Asn396Ser variant in the LIPG gene associated with depressive symptoms.

Authors:  N Amin; O Jovanova; H H H Adams; A Dehghan; M Kavousi; M W Vernooij; R P Peeters; F M S de Vrij; S J van der Lee; J G J van Rooij; E M van Leeuwen; L Chaker; A Demirkan; A Hofman; R W W Brouwer; R Kraaij; K Willems van Dijk; T Hankemeier; W F J van Ijcken; A G Uitterlinden; W J Niessen; O H Franco; S A Kushner; M A Ikram; H Tiemeier; C M van Duijn
Journal:  Mol Psychiatry       Date:  2016-07-19       Impact factor: 15.992

5.  PLD3 variants in population studies.

Authors:  Sven J van der Lee; Henne Holstege; Tsz Hang Wong; Johanna Jakobsdottir; Joshua C Bis; Vincent Chouraki; Jeroen G J van Rooij; Megan L Grove; Albert V Smith; Najaf Amin; Seung-Hoan Choi; Alexa S Beiser; Melissa E Garcia; Wilfred F J van IJcken; Yolande A L Pijnenburg; Eva Louwersheimer; Rutger W W Brouwer; Mirjam C G N van den Hout; Edwin Oole; Gudny Eirkisdottir; Daniel Levy; Jerome I Rotter; Valur Emilsson; Christopher J O'Donnell; Thor Aspelund; Andre G Uitterlinden; Lenore J Launer; Albert Hofman; Eric Boerwinkle; Bruce M Psaty; Anita L DeStefano; Philip Scheltens; Sudha Seshadri; John C van Swieten; Vilmundur Gudnason; Wiesje M van der Flier; M Arfan Ikram; Cornelia M van Duijn
Journal:  Nature       Date:  2015-04-02       Impact factor: 49.962

6.  Common coding variant in SERPINA1 increases the risk for large artery stroke.

Authors:  Rainer Malik; Therese Dau; Maria Gonik; Anirudh Sivakumar; Daniel J Deredge; Evgeniia V Edeleva; Jessica Götzfried; Sander W van der Laan; Gerard Pasterkamp; Nathalie Beaufort; Susana Seixas; Steve Bevan; Lisa F Lincz; Elizabeth G Holliday; Annette I Burgess; Kristiina Rannikmäe; Jens Minnerup; Jennifer Kriebel; Melanie Waldenberger; Martina Müller-Nurasyid; Peter Lichtner; Danish Saleheen; Peter M Rothwell; Christopher Levi; John Attia; Cathie L M Sudlow; Dieter Braun; Hugh S Markus; Patrick L Wintrode; Klaus Berger; Dieter E Jenne; Martin Dichgans
Journal:  Proc Natl Acad Sci U S A       Date:  2017-03-06       Impact factor: 11.205

7.  The Loss of GSTM1 Associates with Kidney Failure and Heart Failure.

Authors:  Adrienne Tin; Robert Scharpf; Michelle M Estrella; Bing Yu; Megan L Grove; Patricia P Chang; Kunihiro Matsushita; Anna Köttgen; Dan E Arking; Eric Boerwinkle; Thu H Le; Josef Coresh; Morgan E Grams
Journal:  J Am Soc Nephrol       Date:  2017-07-18       Impact factor: 10.121

8.  Plasma galectin-3 levels are associated with the risk of incident chronic kidney disease.

Authors:  Casey M Rebholz; Elizabeth Selvin; Menglu Liang; Christie M Ballantyne; Ron C Hoogeveen; David Aguilar; John W McEvoy; Morgan E Grams; Josef Coresh
Journal:  Kidney Int       Date:  2017-08-31       Impact factor: 10.612

9.  Analysis of loss-of-function variants and 20 risk factor phenotypes in 8,554 individuals identifies loci influencing chronic disease.

Authors:  Alexander H Li; Alanna C Morrison; Christie Kovar; L Adrienne Cupples; Jennifer A Brody; Linda M Polfus; Bing Yu; Ginger Metcalf; Donna Muzny; Narayanan Veeraraghavan; Xiaoming Liu; Thomas Lumley; Thomas H Mosley; Richard A Gibbs; Eric Boerwinkle
Journal:  Nat Genet       Date:  2015-04-27       Impact factor: 38.330

10.  Genome-Wide Association Studies of Metabolites in Patients with CKD Identify Multiple Loci and Illuminate Tubular Transport Mechanisms.

Authors:  Yong Li; Peggy Sekula; Matthias Wuttke; Judith Wahrheit; Birgit Hausknecht; Ulla T Schultheiss; Wolfram Gronwald; Pascal Schlosser; Sara Tucci; Arif B Ekici; Ute Spiekerkoetter; Florian Kronenberg; Kai-Uwe Eckardt; Peter J Oefner; Anna Köttgen
Journal:  J Am Soc Nephrol       Date:  2018-03-15       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.